Johnson & Johnson Acquires Yellow Jersey Therapeutics from Numab for $1.25B

Johnson & Johnson to Acquire Ambrx Biopharma in ~$2 Billion All-Cash Deal

January 8, 2024

Pharmaceuticals

Johnson & Johnson announced it has entered into a definitive agreement to acquire Ambrx Biopharma in an all-cash merger transaction valued at about $2 billion (about $1.9 billion net of estimated cash acquired). The deal is intended to add Ambrx’s proprietary synthetic biology and ADC (antibody-drug conjugate) technology platform and its clinical and preclinical oncology pipeline to J&J’s targeted oncology therapeutics efforts.

Johnson & Johnson to Acquire Proteologix, Inc.

May 16, 2024

Biotechnology

Johnson & Johnson entered into a definitive agreement to acquire privately held biotechnology company Proteologix for $850 million in cash, with potential additional milestone payments. The deal is expected to close mid-year 2024 subject to antitrust clearance and customary closing conditions, expanding J&J’s bispecific antibody pipeline for immune-mediated diseases including atopic dermatitis and asthma.

Johnson & Johnson Acquires Intra-Cellular Therapies

April 2, 2025

Healthcare Services

Johnson & Johnson has acquired Intra-Cellular Therapies, paying $132 per share in cash for all outstanding shares, for an equity value of approximately $14.6 billion. The deal adds CAPLYTA (lumateperone) and a clinical-stage pipeline, including ITI-1284, to strengthen J&J’s neuroscience portfolio.

SERB Pharmaceuticals Acquires Y-mAbs Therapeutics

September 16, 2025

Biotechnology

SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.

BioNTech Acquires Neon Therapeutics

January 16, 2020

Biotechnology

BioNTech SE will acquire Neon Therapeutics, Inc. in an all-stock transaction valued at approximately $67.0 million. Neon, a Cambridge-based developer of neoantigen-targeted T cell therapies, will become a wholly owned subsidiary of BioNTech to expand BioNTech’s T cell therapy capabilities and U.S. presence.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.